ATE186551T1 - Medikamente bindendes protein - Google Patents

Medikamente bindendes protein

Info

Publication number
ATE186551T1
ATE186551T1 AT94928616T AT94928616T ATE186551T1 AT E186551 T1 ATE186551 T1 AT E186551T1 AT 94928616 T AT94928616 T AT 94928616T AT 94928616 T AT94928616 T AT 94928616T AT E186551 T1 ATE186551 T1 AT E186551T1
Authority
AT
Austria
Prior art keywords
binding protein
drug binding
assays
relates
encoding same
Prior art date
Application number
AT94928616T
Other languages
English (en)
Inventor
John C Lee
Jerry L Adams
Timothy F Gallagher
David W Green
John Richard Heys
Peter C Mcdonnell
Dean E Mcnulty
James E Strickler
Peter R Young
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/250,975 external-priority patent/US5783664A/en
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of ATE186551T1 publication Critical patent/ATE186551T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT94928616T 1993-09-17 1994-09-16 Medikamente bindendes protein ATE186551T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12317593A 1993-09-17 1993-09-17
US08/250,975 US5783664A (en) 1993-09-17 1994-05-31 Cytokine suppressive anit-inflammatory drug binding proteins

Publications (1)

Publication Number Publication Date
ATE186551T1 true ATE186551T1 (de) 1999-11-15

Family

ID=26821313

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94928616T ATE186551T1 (de) 1993-09-17 1994-09-16 Medikamente bindendes protein

Country Status (14)

Country Link
US (3) US5871934A (de)
EP (1) EP0724588B1 (de)
JP (1) JP3377529B2 (de)
CN (1) CN1048731C (de)
AT (1) ATE186551T1 (de)
AU (1) AU686669B2 (de)
CA (1) CA2171982C (de)
DE (1) DE69421624T2 (de)
DK (1) DK0724588T3 (de)
ES (1) ES2140561T3 (de)
GR (1) GR3032635T3 (de)
NZ (1) NZ274063A (de)
PT (1) PT724588E (de)
WO (1) WO1995007922A1 (de)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
DK0797575T3 (da) * 1994-12-13 2004-02-16 Hoffmann La Roche Imidazolderivater som proteinkinase-inhibitorer, især EGF-R-tyrosinkinase
DK1329226T3 (da) * 1995-03-31 2007-09-24 Xenova Res Ltd Haptenbærerkonjugater til anvendelse i behandling af stofmisbrug
JP4129992B2 (ja) * 1995-12-06 2008-08-06 大日本住友製薬株式会社 新規セマフォリンzおよびそれをコードする遺伝子
WO1997034137A2 (en) * 1996-03-12 1997-09-18 Smithkline Beecham Corporation Methods of the identification of pharmaceutically active compounds
US6235760B1 (en) * 1996-03-25 2001-05-22 Smithkline Beecham Corporation Treatment for CNS injuries
US5948885A (en) 1996-05-20 1999-09-07 Signal Pharmaceuticals, Inc. Mitogen-activated protein kinase p38-2 and methods of use therefor
US6677130B1 (en) 1996-05-20 2004-01-13 Signal Pharmaceuticals, Inc. Mitogen-activated protein kinase p38-2 and methods of use therefor
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
CA2294057A1 (en) 1997-06-13 1998-12-17 Smithkline Beecham Corporation Novel pyrazole and pyrazoline substituted compounds
AU8154998A (en) 1997-06-19 1999-01-04 Smithkline Beecham Corporation Novel aryloxy substituted pyrimidine imidazole compounds
US6489325B1 (en) 1998-07-01 2002-12-03 Smithkline Beecham Corporation Substituted imidazole compounds
US7301021B2 (en) * 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US6562832B1 (en) 1997-07-02 2003-05-13 Smithkline Beecham Corporation Substituted imidazole compounds
TW517055B (en) * 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
WO1999017776A1 (en) 1997-10-08 1999-04-15 Smithkline Beecham Corporation Novel cycloalkenyl substituted compounds
CA2223075A1 (en) * 1997-12-02 1999-06-02 Smithkline Beecham Corporation Drug binding protein
WO1999032121A1 (en) 1997-12-19 1999-07-01 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses
MXPA00006233A (es) 1997-12-22 2002-09-18 Bayer Ag Inhibicion de la actividad de la cinasa p38 utilizando ureas heterociclicas sustituidas.
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
DE69836563T2 (de) * 1997-12-22 2007-05-16 Bayer Pharmaceuticals Corp., West Haven INHIBIERUNG DER p38 KINASE-AKTIVITÄT DURCH DIE VERWENDUNG VON ARYL- UND HETEROARYL-SUBSTITUIERTEN HARNSTOFFEN
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
JP2003525201A (ja) * 1998-08-20 2003-08-26 スミスクライン・ビーチャム・コーポレイション 新規な置換トリアゾール化合物
US6268352B1 (en) * 1998-09-02 2001-07-31 The Regents Of The University Of California Promoters of neural regeneration
WO2000025791A1 (en) * 1998-11-04 2000-05-11 Smithkline Beecham Corporation Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
US20020065296A1 (en) 1999-01-13 2002-05-30 Bayer Corporation Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
WO2000042012A1 (en) 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE538794T1 (de) 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
UA73492C2 (en) * 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
MXPA01008440A (es) 1999-02-22 2002-04-24 Boehringer Ingelheim Pharma Derivados heterociclicos policiclos como agentes anti-inflamatorios..
NZ528846A (en) 1999-03-12 2005-05-27 Boehringer Ingelheim Pharma Compounds useful as anti-inflammatory agents
WO2000055152A1 (en) 1999-03-12 2000-09-21 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
US6287773B1 (en) * 1999-05-19 2001-09-11 Hoeschst-Ariad Genomics Center Profile searching in nucleic acid sequences using the fast fourier transformation
ATE312823T1 (de) * 1999-07-09 2005-12-15 Boehringer Ingelheim Pharma Verfahren zur herstellung heteroarylsubstituierter ureaverbindungen
AU1781601A (en) 1999-11-23 2001-06-04 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
US6759410B1 (en) * 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
EP1233951B1 (de) 1999-11-23 2005-06-01 SmithKline Beecham Corporation 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
ATE305787T1 (de) 1999-11-23 2005-10-15 Smithkline Beecham Corp 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
US6525046B1 (en) 2000-01-18 2003-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
US6608052B2 (en) 2000-02-16 2003-08-19 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
US7235551B2 (en) * 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
CA2410475A1 (en) * 2000-06-01 2001-12-06 Merck & Co., Inc. Use of (di-substituted-phenyl)-pyrimidinyl-imidazole derivatives as jnk-inhibitors
ATE521353T1 (de) * 2000-10-23 2011-09-15 Glaxosmithkline Llc Neues trisubstitutiertes 8h-pyridoä2,3- düpyrimidin-7-onderivat zur behandlung von durch csbp/p38kinase vermittelten krankheiten
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2002063029A1 (en) * 2001-02-02 2002-08-15 Iconix Pharmaceuticals, Inc. Alteration of phenotype due to heterologous genes
EE200300437A (et) 2001-03-09 2004-02-16 Pfizer Products Inc. Triasolopüridiinid kui põletikuvastased ained
CA2440211A1 (en) 2001-03-09 2002-09-19 Pfizer Products Inc. Benzimidazole anti-inflammatory compounds
ES2247271T3 (es) 2001-04-04 2006-03-01 Pfizer Products Inc. Nuevos benzotriazoles como compuestos antiinflamatorios.
US7371763B2 (en) 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
EP1455791A1 (de) * 2001-12-11 2004-09-15 Boehringer Ingelheim Pharmaceuticals Inc. Methode zur verabreichung von birb 796 bs
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
MXPA04007832A (es) 2002-02-11 2005-09-08 Bayer Pharmaceuticals Corp Aril-ureas con actividad inhibitoria de angiogenesis.
MXPA04007830A (es) 2002-02-11 2005-07-01 Bayer Pharmaceuticals Corp Arilureas como inhibidores de cinasa.
ATE386030T1 (de) * 2002-02-25 2008-03-15 Boehringer Ingelheim Pharma 1,4-disubstituierte benzokondensierte cycloalkyl- harnstoffverbindungen zur behandlung von zytokinvermittelten erkrankungen
US20060105445A1 (en) * 2002-07-29 2006-05-18 Klaus Godl Medium and method for enriching, purifying or depleting atp binding proteins from a pool of proteins
US7012143B2 (en) 2002-08-30 2006-03-14 Dombroski Mark A Cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines
US7037923B2 (en) * 2002-08-30 2006-05-02 Pfizer, Inc. Alkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines
US6949652B2 (en) * 2002-08-30 2005-09-27 Pfizer, Inc. Crystalline forms of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-A]pyridine
US7005523B2 (en) * 2002-08-30 2006-02-28 Pfizer Inc. Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines
US20040092547A1 (en) * 2002-08-30 2004-05-13 Pfizer Inc Alkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines
PA8579601A1 (es) * 2002-08-30 2004-05-07 Pfizer Prod Inc Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas
US6803748B2 (en) * 2003-02-03 2004-10-12 Delphi Technologies, Inc. System and method for controlling load dump voltage of a synchronous machine
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
MXPA05012377A (es) * 2003-05-15 2006-05-25 Arqule Inc Derivados de imidazotiazoles e imidazoxazol como inhibidores de p38.
WO2004113274A2 (en) 2003-05-20 2004-12-29 Bayer Pharmaceuticals Corporation Diaryl ureas with kinase inhibiting activity
EA010485B1 (ru) 2003-07-23 2008-10-30 Байер Фамэсьютиклс Копэрейшн Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты)
RU2006124843A (ru) * 2003-12-12 2008-01-20 Уайт (Us) Хинолины, пригодные для лечения сердечно-сосудистого заболевания
WO2006010082A1 (en) * 2004-07-08 2006-01-26 Arqule, Inc. 1,4-disubstituted naphtalenes as inhibitors of p38 map kinase
JP2008517064A (ja) * 2004-10-19 2008-05-22 アークル インコーポレイテッド P38mapキナーゼのイミダゾオキサゾールおよびイミダゾチアゾール阻害剤の合成
EP1865959A2 (de) * 2005-03-25 2007-12-19 Glaxo Group Limited Verfahren zur herstellung von pyrido¦2,3-d pyrimidin-7-on and 3,4-dihydropyrimido¦4,5-d pyrimidin-2(1h)-on-derivaten
UY29440A1 (es) 2005-03-25 2006-10-02 Glaxo Group Ltd Nuevos compuestos
RU2008100039A (ru) * 2005-06-10 2009-07-20 Универсидад Аутонома Де Мадрид (Es) Новый сайт фосфорилирования митоген-активированных протеинкиназ, модифицированные белки и применение
CN1995345B (zh) * 2006-08-31 2010-12-29 辽宁师范大学 重组日本七鳃鳗口腔腺分泌具抗炎功效l-251蛋白
US20110046378A1 (en) * 2008-02-14 2011-02-24 Siemens Medical Solutions Usa, Inc. Novel Imaging Agents for Detecting Neurological Dysfunction
US8932557B2 (en) 2008-02-14 2015-01-13 Eli Lilly And Company Imaging agents for detecting neurological dysfunction
CA2731738A1 (en) * 2008-07-24 2010-01-28 Siemens Medical Solutions Usa, Inc. Imaging agents useful for identifying ad pathology
CN102317293A (zh) * 2008-12-05 2012-01-11 艾科尔公司 Raf抑制剂及其用途
US8691187B2 (en) * 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
CN103739605B (zh) * 2009-03-23 2016-08-17 伊莱利利公司 用于检测神经障碍的显像剂
WO2015119579A1 (en) 2014-02-07 2015-08-13 Agency For Science, Technology And Research 2,4,5-tri-substituted azole-based casein kinase 1 inhibitors as inducers for cardiomyogenesis
US10669528B2 (en) 2015-06-25 2020-06-02 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
WO2017161001A1 (en) 2016-03-15 2017-09-21 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4794114A (en) * 1986-08-19 1988-12-27 Smithkline Beckman Corporation Inhibition of interleukin-1 production by monocytes and/or macrophages
US4780470A (en) * 1986-08-19 1988-10-25 Smithkline Beckman Corporation Inhibition of interleukin-1 by monocytes and/or macrophages
US4778806A (en) * 1986-08-19 1988-10-18 Smithkline Beckman Corporation Inhibition of interleukin-1 production by monocytes and/or macrophages
KR920702621A (ko) * 1989-06-13 1992-10-06 스튜어트 알. 슈터 단핵세포 및/또는 마크로파지에 의한 인터루킨-1 또는 종양회사인자 생성의 억제
US5512473A (en) * 1993-01-29 1996-04-30 Brent; Roger Max-interacting proteins and related molecules and methods
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds

Also Published As

Publication number Publication date
ES2140561T3 (es) 2000-03-01
WO1995007922A1 (en) 1995-03-23
DK0724588T3 (da) 2000-05-15
DE69421624D1 (de) 1999-12-16
US5777097A (en) 1998-07-07
DE69421624T2 (de) 2000-07-20
CN1134704A (zh) 1996-10-30
JP3377529B2 (ja) 2003-02-17
CA2171982C (en) 2000-02-01
PT724588E (pt) 2000-05-31
EP0724588A1 (de) 1996-08-07
GR3032635T3 (en) 2000-05-31
CN1048731C (zh) 2000-01-26
JPH09502873A (ja) 1997-03-25
EP0724588A4 (de) 1998-06-03
EP0724588B1 (de) 1999-11-10
NZ274063A (en) 1997-11-24
HK1012399A1 (en) 1999-07-30
AU686669B2 (en) 1998-02-12
CA2171982A1 (en) 1995-03-23
US5871934A (en) 1999-02-16
AU7798594A (en) 1995-04-03
US5955366A (en) 1999-09-21

Similar Documents

Publication Publication Date Title
ATE186551T1 (de) Medikamente bindendes protein
EP0969093A3 (de) Protein, das Medikamente bindet
NO961115L (no) Humane metabotrope glutamatreseptorsubtyper (HMR4, HMR6, HMR7) og relaterte DNA forbindelser
EP1712623A3 (de) Selektion von Proteinen unter Verwendung von RNA-protein-fusionen
BR0009206A (pt) Isolamento e análise de proteina
CY1105895T1 (el) Χιμαιρικη πρωτεϊνη διαλυτου υποδοχεα/συνδετη ιντepλευκινης-6, αναλογα και αυτης και χρησεις αυτης
DK0692025T3 (da) Gærceller, der er konstrueret således, at de producerer surrogater for proteiner i feromonsystemet, og anvendelser deraf
DE69940198D1 (de) Mikrovorrichtung zum screening von biomolekülen
ES2075196T3 (es) Metodo para el uso y la sintesis de peptidos.
AU1208497A (en) Ligand polypeptides for the g-protein-coupled receptor protein, their production and use
ATE291585T1 (de) Traf-inhibitoren
DE69531958D1 (de) (1-3)-beta-d-glukon-bindungsprotein, antikörper der dieses protein erkennt undverwendung des proteins und antikörper
ATE311443T1 (de) Methoden zur durchforstung (screenen) von proteinen
WO1999003993A3 (en) Suppressors of cytokine signaling; related reagents
BR9710919A (pt) Proteina purificada sr-p70
WO2000001820A3 (en) Nucleic acid molecules encoding nuclear hormone receptor coactivators, and uses thereof
ATE452650T1 (de) Transferrin-fusionsproteinbibliotheken
MX9302488A (es) Proteina humana receptora de glutamato y compuestos de dna relacionados.
DE3582812D1 (de) Dns-fragmente welche fuer peptide kodieren, die faehig sind in vivo die synthese von antihepatitis-a-virus-antikoerpern zu induzieren.
EP0600278A3 (de) Protein und Gen des Glutamatrezeptors.
DK1019500T3 (da) IFN receptor 1-bindende proteiner, DNA, som koder for dem, og fremgangsmåder til modulering af cellulært respons på interferoner
RU94026276A (ru) Рецепторы интерлейкина-12 и антител

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification